Compare Ascendis Pharma A/S (ASND) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Rigetti Computing Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Rigetti Computing Inc trades at $16.3 (market cap $5.50B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× Rigetti Computing Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| ASND | RGTI | |
|---|---|---|
Market Cap | $17.74B | $5.50B |
Sector | Health | Technology |
52-Week High | $277.18 | $56.34 |
52-Week Low | $163.32 | $12.18 |
Enterprise Value | $18.11B | $5.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Rigetti Computing (RGTI) trades at $16.54, down 2.65% on the day, with a bearish technical signal despite recent earnings beats. The company shows severe financial strain with a net income margin of -2,253.59% and negative cash flow from operations of -$58.54M in 2025, though it maintains a debt-free position with $569M cash. Analyst consensus remains strongly bullish with 85.71% buy ratings and a $32.67 price target, highlighting government funding and quantum computing advancements as key catalysts.
The stock presents high-risk, high-reward potential driven by speculative quantum technology growth versus fundamental weaknesses. Near-term risks include cash burn sustainability and commercial adoption timelines, while upside hinges on execution against long-term quantum roadmaps and competitive positioning in a nascent industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
